Evidence map›Paper›PMID 42665722›Full record

Trial reportBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026

Comparison of the Risk of Acute Anterior Uveitis Flare Between Adalimumab and Subcutaneous Infliximab in Patients with Radiographic Axial Spondyloarthritis and Prior Acute Anterior Uveitis: A Randomized Controlled Trial.

Oh Chan Kwon, Soo Min Ahn, Seokchan Hong, Yeon Hong Seo, Min Kim, Joo Yong Lee, Un Chul Park, Seong Joon Ahn, Min-Chan Park, Eun Young Lee and 2 more

Abstract readRandomized Controlled TrialMulticenter StudyComparative Study
PubMed Publisher
In one paragraph

Trial report in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Oh Chan KwonDivision of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Soo Min AhnDivision of Rheumatology, Department of Internal Medicine, College of Medicine, Asan Medical Center, University of Ulsan, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.
Seokchan HongDivision of Rheumatology, Department of Internal Medicine, College of Medicine, Asan Medical Center, University of Ulsan, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.
Yeon Hong SeoDivision of Rheumatology, Department of Internal Medicine, College of Medicine, Asan Medical Center, University of Ulsan, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.
Min KimDepartment of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Joo Yong LeeDepartment of Ophthalmology, College of Medicine, Asan Medical Center, University of Ulsan, Seoul, South Korea.
Un Chul ParkDepartment of Ophthalmology, Seoul National University College of Medicine, Seoul, South Korea.
Seong Joon AhnDepartment of Ophthalmology, Hanyang University College of Medicine, Seoul, South Korea.
Min-Chan ParkDivision of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Eun Young LeeDivision of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Tae-Hwan KimHanyang University Institute for Rheumatology Research, Seoul, South Korea.
Yong-Gil KimDivision of Rheumatology, Department of Internal Medicine, College of Medicine, Asan Medical Center, University of Ulsan, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. bestmd2000@amc.seoul.kr.ORCID http://orcid.org/0000-0002-8029-7355

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation of radiographic axial spondyloarthritis (r-axSpA) and is an important consideration when selecting biological therapy. Although adalimumab (ADA) and infliximab are commonly used in patients with r-axSpA and AAU, direct comparative evidence, particularly between ADA and subcutaneous infliximab (IFX-SC), remains limited.

objectiveThe objective of this study was to compare the risk of AAU flare between ADA and IFX-SC in patients with r-axSpA and a history of AAU.

methodsThis multicenter, head-to-head, randomized, open-label trial enrolled patients with r-axSpA and a documented AAU event within the preceding 2 years. Participants were randomly assigned (1:1) to receive ADA (40 mg every 2 weeks) or IFX-SC (intravenous 5 mg/kg induction followed by subcutaneous 120 mg every 2 weeks) and were followed for 48 weeks. The primary endpoint was AAU flare occurrence. Hazard ratios (HRs) were estimated using Cox proportional hazards models. Secondary endpoints included changes in best-corrected visual acuity (BCVA), r-axSpA disease activity and functional indices, and safety outcomes.

resultsFifty-six patients were randomized (ADA, n = 28; IFX-SC, n = 28). During follow-up, one AAU flare episode occurred in each group. The adjusted HR of IFX-SC (vs ADA) for an AAU flare was 0.496 (95% confidence interval 0.025-9.768, p = 0.645). No significant differences in secondary endpoints were observed between groups (right BCVA, p = 0.622; left BCVA, p = 0.306; Axial Spondyloarthritis Disease Activity Score, p = 0.293; Bath Ankylosing Spondylitis Disease Activity Index, p = 0.262; Bath Ankylosing Spondylitis Functional Index, p = 0.307). Adverse events were similar in frequency and severity, with no new safety signals identified.

conclusionsNo statistically significant differences in AAU flare risk or secondary ocular and rheumatologic outcomes were observed between ADA and IFX-SC over 48 weeks in patients with r-axSpA and prior AAU. These findings suggest that IFX-SC may represent a potential alternative to ADA for AAU flare prevention as well as disease activity control in this population. CLINICAL TRIAL REGISTRATION NUMBER: Clinical Research Information Service (CRIS), Republic of Korea; KCT0007239.

Indexed as

AdalimumabAntirheumatic AgentsAxial SpondyloarthritisInfliximabUveitis, AnteriorAcute DiseaseAdultFemaleHumansInjections, SubcutaneousMaleMiddle AgedAdalimumabAntirheumatic AgentsInfliximab

Identifiers

PMID42665722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.